alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with n-methylaspartate in 4 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (n-methylaspartate) | Trials (n-methylaspartate) | Recent Studies (post-2010) (n-methylaspartate) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 10,408 | 59 | 1,902 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | n-methylaspartate (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Montigny, C; Debonnel, G; Fournier, A; Monnet, FP | 1 |
| Borosky, SA; Clissold, DB; Ferkany, JW; Goode, S; Karbon, EW; Patch, RJ; Pontecorvo, MJ | 1 |
| Bergeron, R; De Montigny, C; Debonnel, G | 1 |
| Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB | 1 |
4 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and n-methylaspartate
| Article | Year |
|---|---|
Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor.
Topics: Animals; Cinnamates; Cyclopropanes; Drug Synergism; Guanidines; Haloperidol; Hippocampus; Male; N-Methylaspartate; Neuropeptide Y; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide Y; Receptors, sigma; Spiperone | 1992 |
Possible cerebroprotective and in vivo NMDA antagonist activities of sigma agents.
Topics: Animals; Anticonvulsants; Brain Diseases; Electroshock; Haloperidol; Hypoxia; Male; Mice; Mice, Inbred Strains; N-Methylaspartate; Nimodipine; Piperidines; Postural Balance; Pyrimidines; Receptors, Opioid; Receptors, sigma; Seizures | 1991 |
Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Topics: 1-Naphthylamine; Animals; Antidepressive Agents; Clorgyline; Electrophysiology; Haloperidol; Male; N-Methylaspartate; Paroxetine; Pyramidal Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sertraline; Tranylcypromine | 1993 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |